According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “
Other research analysts have also issued reports about the stock. Roth Capital reissued a buy rating and set a $17.00 target price on shares of Vascular Biogenics in a research note on Thursday, December 1st. Chardan Capital set a $20.00 price objective on shares of Vascular Biogenics and gave the company a buy rating in a research note on Tuesday, November 29th. Finally, Piper Jaffray Companies reaffirmed an overweight rating and issued a $11.00 price objective on shares of Vascular Biogenics in a research note on Tuesday, February 21st. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $12.90.
Vascular Biogenics (NASDAQ:VBLT) traded up 4.81% during midday trading on Friday, reaching $5.45. The company’s stock had a trading volume of 236,028 shares. Vascular Biogenics has a 52-week low of $3.03 and a 52-week high of $7.58. The firm has a 50-day moving average price of $5.58 and a 200 day moving average price of $5.23. The stock’s market capitalization is $146.62 million.
Vascular Biogenics (NASDAQ:VBLT) last issued its earnings results on Monday, March 27th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. Equities research analysts predict that Vascular Biogenics will post ($0.66) EPS for the current fiscal year.
A hedge fund recently bought a new stake in Vascular Biogenics stock. Knoll Capital Management LP purchased a new position in shares of Vascular Biogenics Ltd (NASDAQ:VBLT) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 860,605 shares of the biopharmaceutical company’s stock, valued at approximately $4,406,000. Vascular Biogenics makes up 7.7% of Knoll Capital Management LP’s portfolio, making the stock its 4th largest position. Knoll Capital Management LP owned about 3.65% of Vascular Biogenics at the end of the most recent reporting period. Hedge funds and other institutional investors own 14.95% of the company’s stock.
About Vascular Biogenics
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vascular Biogenics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd and related companies with MarketBeat.com's FREE daily email newsletter.